We assessed the relative levels of secreted matrix metalloproteinases (MMPs) and plasminogen activators (PAs) in PC-3 cells, prostate fibroblasts and osteoblasts in the presence and absence of VEGF, TGFb1 and bFGF. Fibroblasts and osteoblasts secreted more MMPs -1 and -2 than did PC-3 cells, while PC-3 s contributed the majority of PAs. MMP-1 expression was downregulated by transforming growth factor b-1 (TGFb1) treatment in prostate fibroblasts and upregulated by basic fibroblast growth factor (bFGF) in both stromal lines. In PC-3 cells, TGFb1 and bFGF increased urokinase plasminogen activator secretion. TGFb1 decreased tissue plasminogen activator secretion in all cell lines. Prostate cancer cells associated with fibroblasts or osteoblasts have a variety of MMPs and PAs to facilitate matrix degradation.
Introduction
During metastasis, a cancer cell transits through several tissue compartments and encounters multiple cell types including normal epithelium, other tumor cells, prostate fibroblasts, endothelium and cells at the secondary site. In addition, the metastatic cell interacts with the extracellular matrix and with matrix-bound growth factors, and cytokines and proteases. Dissolution of the extracellular matrix structure between tissue compartments is a critical determinant of successful migration. This process appears to be regulated to a large extent by the matrix metalloproteinases (MMPs) and plasminogen activators (PAs).
1,2 Several MMPs have been linked to prostate cancer metastasis including MMP-1, 3 -2 and -9, 4,5 -3, 6 -7 3,7 and -14. 8 Many MMPs contributing to tumor invasion are produced primarily by stromal cells; 9 however, prostate cancer cell production of specific MMPs such as MMP-9 can also play essential roles. 4, 10 The PAs, urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), activate several MMPs such as MMP-1, -2, -3, -9, -12 and -13 [11] [12] [13] in addition to activating plasmin. Of these two PAs, uPA has been more strongly associated with prostate cancer 12 where its expression correlates with invasion and tumor stage.
14 Since the uPA enzyme has both proliferative and proteolytic effects on prostate cancer cells, it could play a role in both primary tumor growth and metastasis. 15, 16 Both MMPs and PAs are regulated by growth factors present in both the prostate and osseous environments. Vascular endothelial growth factor (VEGF), transforming growth factor b-1 (TGFb1) and basic fibroblast growth factor (bFGF) were chosen for study in this report. The association of TGFb1 with prostate cancer progression and invasion is well documented. 4, 17, 18 TGFb1 could play a particularly relevant role in bone metastasis as this growth factor is stored in greatest quantities in bone matrix and is produced by osteoblasts during remodeling. 19 TGFb1 has numerous stimulatory and repressive effects on MMP expression in various cancer cell lines (see www.rndsystems.com). In some prostate cancer lines, TGFb1 decreases MMP-1 20 and increases MMP-2 and -9. 4, 5 TGFb1 generally upregulates uPA in cancer cells [21] [22] [23] including prostate 19 as well as in normal cells such as macrophages 24 and synovial fibroblasts.
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TGFb1 effects on tPA expression in various cell types is less extensively documented; however, reported effects indicate a downregulatory role. 26, 27 VEGF is strongly associated with angiogenic growth and induces MMP-1, -2, -3, and -9. 28, 29 It is expressed by prostate cancer cells and at highest levels by those with a neuroendocrine phenotype. 30 VEGF expression increases with Gleason score, androgen independence and metastasis. 30, 31 bFGF simulates prostate cancer cell growth as well as angiogenesis and is correlated with prostate tumor aggressiveness. 32 It is secreted by both prostate cancer cell lines as well as by prostate and bone stromal cells. 32, 33 bFGF is reported to stimulate several MMPs including the gelatinases, MMP-2 and -9. 34 In order to best target proteinases for inhibition in a relatively selective manner, the types and quantities of proteases available at the primary site and secondary sites such as bone must be defined and this definition must take into account the potential stimulatory or inhibitory effects of prostate cancer-associated growth factors. In this study, we assessed the relative levels of secreted MMPs and PAs in cultures of PC-3 prostate cancer cells, and in normal stromal cells the cancer cell is likely to encounter by using normal human prostate fibroblasts and osteoblasts. We also tested the effects of three growth factors on levels of MMPs and PAs in the cell lines grown separately and in coculture (c.c.) in order to understand the relative contributions and regulation of potential proteinase targets.
Materials and Methods

Cell culture
The human prostate cell line PC-3, derived from an osseous metastasis, was obtained from the American Type Culture Collection (ATCC). This line was routinely propagated in Ham's F12-K medium (Sigma) plus 10% FBS. Prostate stromal cells (PrSC) and human osteoblasts cells (NHOst) were purchased from Clonetics Corp. For conditioned medium preparation, all cell lines were grown to 75% confluence in 15 cm diameter dishes and then cultured in Ham's F12 K medium (serum free) for 48 h. C.C.s between PC-3 cells and fibroblasts/osteoblast were seeded at a density of 10,000 cells per square centimeter of each cell line then grown to 75% confluence (the time period required for c.c. to achieve this density was approximately 1 day). Therefore, the c.c. media represent approximately a 1 : 1 ratio of each cell line or 10,000 cells of each type per lane.
Reagents
TGFb1 was purchased from R&D Systems (Minneapolis) and used at 2 ng/ml. bFGF (Calbiochem) was used at 1 ng/ml and rh-VEGF (Oncogene Research) was used at 20 ng/ml. Antibodies for MMP-1 (NeoMarkers, Fremont, CA, USA), MMP-3 (NeoMarkers), MMP-7 (BioMol and Oncogene Science), uPA (Molecular Innovations polyclonal) and tPA (Molecular Innovation, polyclonal) were used in Western blot analyses.
Substrate gel zymography
Conditioned media (20 ml) were collected from cultures and concentrated approximately 40-fold (Centricon Plus-20 10,000 NMWL). All media samples were conditioned for 2 days. Cell numbers from the culture plates used to condition the media were counted and media were loaded into lanes as equal cell number equivalents of 20,000 cells of conditioned medium per lane. Type IV gelatinase activity was assayed through acrylamide gel zymography as previously described. 4 Following electrophoresis, gels were soaked 3 Â 20 min in a solution of 50 mM Tris-HCl (pH 7.4), containing 2.5% (v/v) Triton X-100, then incubated at 371C overnight in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM CaCl 2 . Zymograms were developed by fixation/staining (methanol : acetic acid : H 2 O (40 : 10 : 50) with 0.05% Coomassie brillant blue dye), then destained to reveal clear bands of protein degradation.
Western blot analyses
Conditioned medium samples were electrophoresed under nonreducing (native) conditions through 10% SDS-polyacrylamide gels, then transferred to polyvinylidene difluoride (PVDF) membranes as described. 35 Membranes were blocked for 1 h in 4% nonfat dry milk/1% BSA in 140 mM NaCl, Tris-HCl, pH. 7.5 at room temperature, then incubated with antibodies overnight at 41C. Immunoblots were developed using enhanced chemiluminesence (Western Lighting, PerkinElmer Life Sciences, Boston, MA, USA).
Results
Western blotting and gelatin zymography reveal that fibroblasts and osteoblasts secrete greater levels of detectable MMPs than PC-3 cells on a cell number basis.
Immunoreactive MMP-1 was detected in the conditioned medium (c.m.) of both PrSC and NHOst cells ( Figure 1) ; however, MMP-3 and -7 were not found (data not shown). None of these MMPs were detectable in media conditioned by PC-3 cultures. Gelatin zymography revealed MMP-2 (gelatinase A) activity but not MMP-9 (gelatinase B) activity in c.m. from both PrSC and NHOst cells, and again neither MMP was detected in PC-3 media. While growth factors did not alter MMP-2 secretion from fibroblasts or osteoblasts, MMP-1 secretion was abolished from TGFb1-treated PrSC cells but was increased in both fibroblast and osteoblast media following bFGF treatment.
C.C.s of PrSC or NHOst cells with PC-3 cells responded C.C.s to growth factors similarly to PrSC and NHOst cells alone.
bFGF addition to PC-3 and PrSC c.c.s produced an increase in MMP-1 secretion that was greater than that Figure 2) ; however, the lack of responses of this c.c. to VEGF and TGFb1 was similar to PrSC cells cultured alone. C.C.s of PC-3+NHOst cells responded similarly to NHOst cells alone in secretion of MMP-1. As observed with individual culture of fibroblasts and osteoblasts, there were no growth factor effects on secreted activity of MMP-2 and no detection of MMP-9. Medium from HT-1080 fibrosarcoma cells was included in the PC-3+PrSC gel as a positive control showing the migration of gelatinase activities corresponding to MMP-2 and -9. In both c.c.s, we noted that MMP-1 existed in the latent form and a lower migrating active band (Figure 2 ), while the active band was absent in PrSC-alone and weak in NHOst-alone culture media (Figure 1 ).
Secreted PA levels are greater in PC-3 c.m. than in either prostate fibroblasts or osteoblasts Western blots (nondenaturing conditions) demonstrated higher levels of PAs in PC-3 media than in medium from osteoblasts or prostate fibroblasts (Figure 3 ). These blots revealed not only the free PAs but also instances of PA bound to an inhibitor, plasminogen activator inhibitor (PAI), which is approximately 43 kDa. The identity of the PAI band was verified by incubating membranes with anti-PAI-1 (data not shown). PAI complexes with uPA were not evident in PC-3 cells alone and levels were very low in PrSC and NHOst cells, but were apparent in c.c.s of prostate+fibroblast or osteoblast cells. The PAI-tPA complex was seen in PC-3 and NHOst medium but not in PrSC medium, which contained no detectable tPA. The PAI-tPA complex was seen in both c.c. conditions. The migration of these complexes in native gels corresponded to the predicted combined molecular weights of approximately 91 kDa for uPA-PAI and 108 kDa for tPA-PAI.
Growth factor stimulation alters secreted levels of PAs in both PC-3 and stromal cells
Of the three growth factors tested, TGFb1 had the most pronounced effect on PA secretion. High constitutive uPA levels in PC-3 media were increased by TGFb1 as well as by bFGF treatment (Figure 4, upper panel) . TGFb1 increased levels of PAI-1 and in PC-3 cultures, this PAI-1 is detectable as a PAI-1-uPA complex. TGFb1 had an opposite effect on uPA levels in PrSC cultures and repressed uPA levels. NHOst cells responded to TGFb1 as did PC-3 cells with an increase in both free and bound uPA. C.C.s behaved similarly to PC-3 cells alone in that TGFb1 induced uPA secretion; however, in both c.c. conditions, larger baseline levels of the PAI-uPA 
Regulation of MMPs and plasminogen activators
K Forbes et al complex were visible and higher detected levels of this complex were seen after TGFb1 stimulation. VEGF had no effect on secreted uPA levels in these cells or c.c.s. bFGF induced uPA in the PrSC and NHOst lines, but levels of uPA were much lower in these lines compared to PC-3 cells and the c.c. media showed no significant increase in unbound uPA levels.
In contrast to its effect on uPA secretion, TGFb1 repressed secretion of unbound tPA in these cultures (Figure 4, lower panel) . This level of repression was mild in PC-3 cells alone, but pronounced in PrSC and in both c.c. Because of the induction of PAI-1, TGFb1 treatment of PC-3 cells resulted in a shift to a greater ratio of bound tPA; however, the levels of unbound tPA in PC-3 media were still appreciable-much higher than levels in either PrSC or NHOst cells (levels of free tPA in NHOst c.m. were too low to detect).
VEGF had no apparent effect on quantities of tPA in the c.m. under these conditions. bFGF treatment increased unbound tPA levels in PC-3 and PrSC cultures and increased PAI-bound tPA levels in NHOst cells. However, in c.c., the levels of tPA contributed by fibroblasts or osteoblasts were likely overwhelmed by high levels contributed by PC-3 cells, and therefore no significant increases in tPA were observed in c.c. conditions.
Discussion
Prostate cancer cells have a selective interplay with prostate and bone stromal cells. 36 Our results show that fibroblasts and osteoblasts secrete more detected MMPs when normalized by cell number than do PC-3 cells, while PC-3 cells contribute the majority of PAs. The primary fibroblast and osteoblast MMPs found in our assays were MMP-1 and -2. We found no MMP-3 or -7; however, the absence of these MMPs in some prostate cancer cell lines including PC-3 20,37,38 and osteoblasts 3, 39 is consistent with previous reports. While MMP-2 expression in fibroblasts/osteoblasts was not influenced by the three tested growth factors, MMP-1 expression was downregulated by TGFb1 treatment similar to the effects reported with other mesenchyme-derived cells. 40, 41 MMP-1 is also reported to be downregulated in PC-3 cells following TGFb1 treatment; 20 however, we found no detectable levels of MMP-1 at the concentration of media we used. In the stromal-epithelia context we have analyzed, it appears that the relative contribution of MMP-1 from PC-3 cells alone is minor, although MMP-1 secretion by prostate cancer cells could certainly play important roles in other stages of metastasis. Although TGFb1 inhibited MMP-1 secretion from fibroblasts/osteoblasts, our data also show that MMP-1 secreted activity can be enhanced in osteoblast and prostate fibroblast cells by other growth factors such as bFGF. 42 demonstrated that c.c. of PC-3 and human papilloma virus-immortalized prostate fibroblast cell lines leads to increased levels of MMP-9 in the prostate line; however, we could not detect MMP-9 at the level of 20,000 cells/lane c.m. used. Given the pronounced levels of MMP-2, which has similar substrate profile to MMP-9, 43 it seems that gelatinase activity in c.c. is well covered even without MMP-9. In addition, perhaps our use of nontransformed fibroblasts or different PC3/fibroblast ratios explains the absence of MMP-9 modulation.
PC-3 cells secreted comparatively greater levels of both PAs than did fibroblasts or osteoblasts (comparisons between cells in Figure 3 were made on the same gel; however, comparisons between different untreated controls in Figure 4 cannot be made). Levels of secreted free uPA were enhanced by TGFb1 treatment despite the known TGFb1 induction of PAI-1. 44 This inhibitor could be seen bound to the uPA and tPA immunoreactive bands. Interestingly, c.c. conditions resulted in elevated levels of PAI-PA complexes. This could have resulted from increased secretion of PAI-1 induced by growth factors exchanged in the c.c. conditions. PAI expression revealed through the PAI-uPA complexes was not apparent in NHOst cultures in which most uPA was free, but was apparent in tPA immunoblots in which almost all secreted tPA by these osteoblasts was bound by inhibitor. TGFb1 reduced free uPA in fibroblast cultures; however, in PC-3+PrSC (and PC-3+NHOst cocultures), the net effect of TGFb1 treatment was an increase in uPA implying that in c.c., the inducement of PAs by the PC-3 cells counters even the moderate repression of PA secretion by PrSC or NHOst cells. Although TGFb1 inhibited levels of tPA in all three cell types, there were large quantities of available uPA enhanced by TGFb1 treatment; thus, it is possible that even without tPA, uPA levels in c.c. would sufficiently activate pericellular plasmin. Since the PC-3 cell is androgen-independent, we could not assess the potential influence of androgen stimulation in these studies; however, previous reports using androgen receptortransfected PC-3 cells have demonstrated that androgens repress uPA transcription and secretion, and that this repression is lost in androgen-insensitive cells. 45, 46 Therefore, increased uPA expression during prostate cancer progression could result from the loss of androgen repression and the stimulation by factors such as TGFb1.
Collectively, these data suggest that prostate cancer cells associated with prostate fibroblasts or osteoblasts have available to them a mix of PAs and MMPs that are enhanced in the presence of TGFb1 and bFGF, growth factors which are associated with both primary and bone metastasis sites. This mix of proteinases could result in plasmin-mediated activation of MMPs as well as in independent effects on matrix dissolution. Given the recent failures of several MMP inhibitors (MMPIs) in trials, 43 it seems that a combination of MMPIs and serine protease inhibitors and perhaps inhibitors of growth factor that induce PAs may be necessary to attack prostate cancer proteinase activities.
